

Published in final edited form as:

J Mol Cell Cardiol. 2009 June ; 46(6): 858–866. doi:10.1016/j.yjmcc.2008.11.019.

Cardioprotective Signaling to Mitochondria

Keith D. Garlid^{1,*}, Alexandre D.T. Costa², Casey L. Quinlan¹, Sandrine V. Pierre³, and Pierre Dos Santos⁴

¹Department of Biology, Portland State University, Portland, OR, USA, 97201-0751

²Instituto Carlos Chagas (Fiocruz), Rua Prof. Algacyr Munhoz Mader 3775, Curitiba, PR, Brazil, 81350-010

³Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, Ohio

⁴INSERM Unit 828, University Victor Segalen-Bordeaux 2, University Hospital of Bordeaux, Bordeaux, France.

Abstract

Mitochondria are central players in the pathophysiology of ischemia-reperfusion. Activation of plasma membrane G-coupled receptors or the Na, K-ATPase trigger cytosolic signaling pathways that result in cardioprotection. Our working hypothesis is that the occupied receptors migrate to caveolae, where signaling enzymes are scaffolded into signalosomes that bud off the plasma membrane and migrate to mitochondria. The signalosome-mitochondria interaction then initiates intramitochondrial signaling by opening the mitochondrial ATP-sensitive K⁺ channel (mitoK_{ATP}). MitoK_{ATP} opening causes an increase in ROS production, which activates mitochondrial protein kinase C epsilon (PKCε), which inhibits the mitochondrial permeability transition (MPT), thus decreasing cell death. We review the experimental findings that bear on these hypotheses and other modes of protection involving mitochondria.

Keywords

mitochondrial K_{ATP} channel; protein kinase C; reactive oxygen species; permeability transition; signaling pathways

1. Mitochondria : the target for ischemia-reperfusion injury and cardioprotection

Mitochondria are effectors of both ischemia-reperfusion injury (IRI) and cardioprotection. As pointed out 30 years ago by Jennings and Ganote [1], the heart is strictly aerobic and consequently extremely vulnerable to a decrease in oxygen supply. Thus, ischemia causes profound and immediate mitochondrial derangements. These include cessation of ATP synthesis, inhibition of respiration, and a drop in $\Delta\Psi$. This is accompanied during ischemia by cellular changes, especially an increase in Ca²⁺ and phosphate, and, during reperfusion, by large increases in reactive oxygen species (ROS) originating from the respiratory chain [2,3]. Together, these factors promote opening of the mitochondrial permeability transition (MPT),

*corresponding author, Dr. Keith D. Garlid, Department of Biology, Portland State University, Portland, OR, USA, 97201-0751, Fax: +1 503 725 3888, email: E-mail: garlid@pdx.edu .

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

a high-conductance pore in the inner mitochondrial membrane, which is the main cause of necrotic cell death in IRI [4–8]. Consequently, as pointed out by Weiss, et al. [4], cardioprotection by preconditioning or postconditioning must ultimately involve the prevention of MPT.

In addition to their role as mediators of cell death, mitochondria have been shown to be major effectors of diverse self-defense mechanisms, including ischemic pre- and post-conditioning [7,9–11]. These and other conditioning protocols have been shown to require opening of the mitochondrial ATP-sensitive K⁺ channel (mitoK_{ATP}) and inhibition of MPT opening. Since cardioprotection involves both mitoK_{ATP} opening and a decrease in MPT opening, it is reasonable to hypothesize that these two phenomena are part of the same signaling pathway. Indeed, this connection has been demonstrated [12], and will be discussed in this review.

This review describes our current understanding of the signaling mechanisms that originate at plasma membrane receptors, go to mitochondria, and terminate with MPT inhibition. For space reasons, we have not discussed mechanisms for the prevention of apoptosis. For different perspectives, readers are referred to excellent reviews by other authors [13–18].

2. Receptor-mediated signaling to open mitoK_{ATP}

2.1 G_i-protein coupled receptor (GPCR) pathways

Ischemic preconditioning (IPC) and ischemic postconditioning are receptor-mediated processes that are triggered by GPCR agonists released by the ischemic heart, primarily bradykinin, opioid peptides, and adenosine [19]. Other GPCR ligands, including acetylcholine, catecholamines, endothelin, and angiotensin II, are also cardioprotective [20–24], but they were found not to be physiological triggers of IPC [14]. A composite diagram of the GPCR signaling pathways is given in Fig. 1. GPCR signaling has been extensively studied by Downey and Cohen and their coworkers, and is the subject of an excellent review by these authors [14]. It should be emphasized that each G_i-coupled receptor ligand triggers its own unique signaling cascade. Opioids and acetylcholine instigate transactivation of the epidermal growth factor receptor (EGFR), leading to downstream activation of phosphatidylinositol 3-kinase (PI3-K) and Akt. Bradykinin also induces activation of PI3-K and Akt, but without transactivation of EGFR. These two pathways then converge and ultimately lead to mitoK_{ATP} opening and production of ROS. The adenosine signaling pathway has not yet been fully characterized. MitoK_{ATP} opening is not involved during the *trigger* phase of adenosine preconditioning (i.e., when 5-HD administration brackets adenosine perfusion) [25], but mitoK_{ATP} opening is required during the *mediator* phase (i.e., when 5-HD administration precedes ischemia) [26–29].

Protection afforded by all of the trigger substances is blocked by PKC inhibitors, and PKC, probably PKCε, is thought to be a common target of cardioprotective signaling [14]. It has been difficult to localize the critical PKCε, because multiple PKCε isoforms participate in cardioprotection [30]. In ouabain signaling, PKCε acts proximally in conjunction with EGFR transactivation [31]. The adenosine A1 receptor is believed to directly stimulate PLC and PLD to activate PKC [21]. These PKCs are cytosolic. As discussed below, two PKCε isoforms regulate mitoK_{ATP} and MPT at the level of the inner mitochondrial membrane [32]. Thus, the physiological effect of PKCε activation depends entirely on its location and not on its biochemistry, which appears to be invariant.

2.2 Non-GPCR pathways of protection - digitalis

Cardiac glycosides are classic inhibitors of the plasma membrane Na⁺/K⁺-ATPase, but this enzyme also has important non-canonical functions that are triggered by digitalis. Thus, ouabain interaction with the Na, K-ATPase activates src kinase, causing formation of a "binary

receptor” that phosphorylates and assembles other proteins into signaling modules that transmit signals to intracellular compartments [33,34]. Ouabain signaling has been shown to depend on mitoK_{ATP} opening and mitochondrial ROS production [35]. Ouabain is cardioprotective in rat heart [31,36,37], and this cardioprotection is blocked by the mitoK_{ATP} blocker 5-hydroxydecanoate (5-HD), the ROS scavenger N-2-mercaptopyrionylglycine (MPG), and the src kinase inhibitor PP2 [36]. It is interesting to note that, whereas inhibition of the pump and consequent increase in intracellular Na⁺ and Ca²⁺ is required for positive inotropy, ouabain cardioprotection occurs at doses (about 10 μM in rat) that do not produce significant enzyme inhibition [37] or increased contractility [31,36,37]. These distinctions further emphasize the dissociation of the pumping and signaling functions of Na,K-ATPase. Ouabain cardioprotection does not depend on guanylyl cyclase or PKG activities, showing that this signaling pathway differs from that triggered by GPCR agonists [36]. Ouabain-induced inotropy also requires mitoK_{ATP} opening and ROS production [36,38].

The rat heart Na,K-ATPase exhibits a low sensitivity to cardiac glycosides; however, we have observed qualitatively similar phenomena in the ouabain-sensitive rabbit heart. Thus, cardioprotection occurs at lower ouabain doses than those required for inotropy, and both cardioprotection and inotropy require mitoK_{ATP} opening (S. Pierre, unpublished data).

3. From receptor to mitochondria by signalosomes

We propose that cardioprotective signals are transmitted to mitochondria by signalosomes, which are vesicular, multimolecular signaling complexes that are assembled in caveolae and deliver signals to the mitochondrial outer membrane (MOM) [39]. A diagram of the signalosome hypothesis is presented in Fig. 2.

3.1 Rationale

Signaling cascades such as the one portrayed in Fig. 1 must occur rapidly and precisely. We consider it unlikely that these spatio-temporal requirements can be met by random diffusional collisions. Cytosolic proteins are extensively hydrated, and the organization of this water causes a phase separation from bulk cytosolic water. Minimization of the phase boundary, in turn, causes proteins to coalesce within their common hydration phase [40]. If the proteins of the cardioprotective signaling pathway were randomly distributed in the cytosol, they too would coalesce within the hydration phase, with losses of directionality and specificity. Accordingly, we suggest that the signaling cascade is compartmentalized to promote metabolic channeling and that the entire reaction sequence moves through the cytosol as a unit. This hypothesis agrees with and extends the proposal by Ping and coworkers [41,42] that intracellular signaling involves assembly and regulation of multiprotein complexes.

3.2 The signalosome hypothesis

Upon activation, GPCR migrate to caveolae, where caveolins organize and compartmentalize receptors and signaling molecules [43–49]. Caveolae are 50–100 nm membrane invaginations that are rich in cholesterol, sphingolipids, and caveolin proteins [50]. EGFR, the Src family of tyrosine kinases, G-protein α-subunits, PKC isoforms, and transporters such as the Na/K-ATPase have been found to associate with caveolins, which also regulate the activity of many of these proteins [50–56]. Caveolar assembly of the signaling platform is followed by budding off and internalization [57]. Receptor endocytosis has been observed for both GPCRs [45,47, 58–60] and the α1-subunit of Na,K-ATPase [61]. We propose, therefore, that the receptor-specific signaling platform is assembled in caveolae, then separates and internalizes as a signalosome. The signalosome migrates via the cytoskeleton to mitochondria, where it binds to receptors on the MOM, designated in Fig. 2 as R1 (for GPCR-induced signalosomes) and R2 (for ouabain-induced signalosomes). The terminal kinase of the signalosome

phosphorylates its specific receptor, which causes the signal to be transmitted across the MOM and intermembrane space to PKC ϵ 1 on the mitochondrial inner membrane. This is followed by the intramitochondrial signaling pathway described in Section 4 and Fig. 4.

3.3 Experimental evidence for signalosome-mediated mitoK_{ATP} opening

We developed protocols for purifying signalosomes from hearts subjected to various preconditioning or postconditioning protocols and then assayed their functional activity [39]. When the signalosome fractions were added to mitochondria from untreated hearts, they caused mitoK_{ATP} opening, as shown in Fig. 3. Based on the finding that functionally active signalosomes were obtained from hearts exposed to bradykinin, ouabain, ischemic preconditioning, and ischemic postconditioning (Fig. 3), we conclude that this is a general mechanism of signal transmission. Signalosome preparations also inhibited MPT when added to mitochondria from untreated hearts. The signalosomes were dissolved by the cholesterol binding agent methyl- β -cyclodextrin and were resistant to Triton X-100. These properties support their origin in caveolae. Electron microscopy reveals that the signalosomes are 100–140 nm in diameter and can be decorated with immunogold labeled caveolin 3 antibodies [39]. The signalosome induced by bradykinin stimulation contains eNOS, guanylyl cyclase, and cGMP-dependent protein kinase (PKG), and we were able to demonstrate the participation of each of these enzymes in the mitoK_{ATP} assay when proper substrates were supplied (Quinlan and Garlid, unpublished).

3.4 Signalosomes phosphorylate MOM receptors

As shown in Fig. 3, addition of signalosomes from preconditioned hearts to mitochondria from non-preconditioned hearts results in activation of the mitoK_{ATP}. Activity of signalosomes induced by GPCR-mediated protection (bradykinin, IPC, and postconditioning) is inhibited by KT5823, and we conclude that GPCR signalosomes use PKG as the terminal kinase that interacts with mitochondria. In contrast, the activity of signalosomes induced by ouabain is not inhibited by KT5823, in agreement with the finding that KT5823 does not block protection by ouabain [36]. Activity of the ouabain signalosome is inhibited by preincubation with ϵ V₁₋₂ and PP2 (both are required), indicating that the terminal kinases are PKC ϵ and Src kinase. We have found that recombinant PKG [32,62] or recombinant PKC ϵ plus Src (Quinlan and Garlid, unpublished) can also induce mitoK_{ATP} opening in isolated mitochondria.

That the signalosomes interact with the MOM was demonstrated by the finding that neither the signalosomes nor the recombinant terminal kinases induce mitoK_{ATP} opening in mitoplasts lacking the MOM [32,39]. That signalosomes interact by phosphorylation was demonstrated by the finding that activity was blocked in the presence of the Ser/Thr phosphatase PP2A (Fig. 3). The ouabain signalosome was also blocked by tyrosine phosphatase, confirming the action of its Src kinase.

We have not yet determined the molecular identity of R1. R2 is an endogenous MOM MAP kinase, as revealed by Western blot showing increased phosphorylation of p38 MAPK (Thr 180/Tyr 182) after the heart was treated with ouabain and functional studies showing that the MAP kinase inhibitor SB203580 blocked mitoK_{ATP} opening by the ouabain signalosome (Quinlan and Garlid, unpublished studies).

3.5 Signal transmission from MOM to PKC ϵ 1

Signalosome-dependent mitoK_{ATP} opening is also blocked by the PKC ϵ inhibitors cherythrine and ϵ V₁₋₂ [62], confirming a role for PKC ϵ (“PKC ϵ 1” in Fig. 2), which is discussed in the next section. Signaling from R1 or R2 to PKC ϵ 1 is not prevented by MPG, and therefore this step does not involve ROS. This is all we know at this stage about the nature of the link between the MOM receptors and PKC ϵ 1.

4. Intramitochondrial signaling

The diagram in Fig. 4 summarizes several years of studies on intramitochondrial signaling [12,32,39,62–66]. The primary function of this pathway is to inhibit MPT opening, which is widely considered to be the cause of cell death after ischemiareperfusion [5,6,11].

4.1 Step one - opening $\text{mitoK}_{\text{ATP}}$ by activation of $\text{PKC}\epsilon$

Ischemic preconditioning, ischemic postconditioning, and pharmacological preconditioning by plasma membrane receptor agonists cause $\text{mitoK}_{\text{ATP}}$ opening by activating a $\text{PKC}\epsilon$ that is constitutively expressed in mitochondria and associated with the mitochondrial inner membrane [64]. The $\text{PKC}\epsilon$ -specific peptide agonist $\Psi\epsilon\text{RACK}$ and the $\text{PKC}\epsilon$ agonists H_2O_2 , NO, and phorbol 12-myristate 13-acetate (PMA) each open $\text{mitoK}_{\text{ATP}}$ (see Fig. 5) [32]. That these agents were acting via $\text{PKC}\epsilon$ (“ $\text{PKC}\epsilon$ 1” in Fig. 4) was verified by showing that the $\text{PKC}\epsilon$ -specific binding antagonist ϵV_{1-2} blocked all four modes of $\text{PKC}\epsilon$ activation of $\text{mitoK}_{\text{ATP}}$ but did not block $\text{mitoK}_{\text{ATP}}$ opening by diazoxide [32,64]. Neither the $\text{PKC}\epsilon$ -specific peptide antagonist, δV_{1-1} nor a scrambled analog of ϵV_{1-2} had any effect on H_2O_2 -dependent $\text{mitoK}_{\text{ATP}}$ opening. Moreover, the PKC inhibitor Gö6983, which inhibits $\text{PKC}\alpha$, $\text{PKC}\beta$, $\text{PKC}\gamma$, and $\text{PKC}\zeta$, did not block $\text{PKC}\epsilon$ -dependent $\text{mitoK}_{\text{ATP}}$ opening, excluding a role for these isoforms [62].

Jaburek, et al. [64] showed that $\Psi\epsilon\text{RACK}$ and ϵV_{1-2} open $\text{mitoK}_{\text{ATP}}$ in liposomes reconstituted with partially purified $\text{mitoK}_{\text{ATP}}$. Thus, $\text{mitoK}_{\text{ATP}}$ and $\text{PKC}\epsilon$ copurify and remain associated during multiple purification steps carried out in the presence of Triton X-100. This, together with the finding that $\text{PKC}\epsilon$ remains associated with mitochondria in mitoplasts [12], suggests that $\text{PKC}\epsilon$ and $\text{mitoK}_{\text{ATP}}$ are part of a functional complex. When given access in mitoplasts to the mitochondrial inner membrane (“MIM”), PP2A prevented $\text{mitoK}_{\text{ATP}}$ -dependent swelling induced by $\text{PKC}\epsilon$ agonists [32], and we conclude that $\text{PKC}\epsilon$ -dependent $\text{mitoK}_{\text{ATP}}$ opening requires phosphorylation, perhaps of $\text{mitoK}_{\text{ATP}}$ itself.

$\text{PKC}\epsilon$ requires anionic phospholipids for activity, a requirement met in this case by cardiolipin, which is abundant in mitochondria. $\text{PKC}\epsilon$ is activated physiologically by diacylglycerol (or phorbol ester) or by a sulfhydryl oxidizing agent, such as H_2O_2 [67] or NO [32]. PMA or H_2O_2 open up one of the two zinc fingers in $\text{PKC}\epsilon$ [68,69]. $\Psi\epsilon\text{RACK}$, PMA, H_2O_2 , or NO cause conformational changes that expose the substrate domain on $\text{PKC}\epsilon$ and cause its binding to its RACK (receptor for activated C kinase [70]). $\Psi\epsilon\text{RACK}$ is a $\text{PKC}\epsilon$ -specific peptide agonist that acts by regulating intramolecular $\text{PKC}\epsilon$ binding, and ϵV_{1-2} is a $\text{PKC}\epsilon$ -specific peptide antagonist that acts by preventing protein-protein interactions between $\text{PKC}\epsilon$ and its binding protein [70–72]. Murriel and Mochly-Rosen [73] found that $\Psi\epsilon\text{RACK}$ protected cardiac cells from ischemic damage, whereas ϵV_{1-2} caused a loss of protection.

4.2 Step two - mitochondrial K^+ uptake and its consequences

Once $\text{mitoK}_{\text{ATP}}$ is opened, the increase in K^+ uptake leads to several changes in the matrix. Electrophoretic K^+ influx is balanced by electrogenic H^+ efflux driven by the respiratory chain. Uncompensated, this would cause an increase of matrix pH of about 2 pH units. Partial compensation is provided by electroneutral uptake of substrate anions, such as phosphate. The compensation is partial because the concentration of phosphate in the cytosol is much lower than that of K^+ , and this imbalance leads to matrix alkalization [65,66,74].

Matrix alkalization now releases the K^+/H^+ antiporter from inhibition by matrix protons [75], causing K^+ efflux to increase in response to increased K^+ uptake until a new K^+ steady state is achieved. The uncoupling caused by increased futile cycling of K^+ induces is about 3% of the maximum activity of the electron transport chain. This low level of uncoupling reflects

the low activity of mitoK_{ATP}, a property that is essential for mitochondrial survival. Thus, if we add sufficient valinomycin to double the mitoK_{ATP}-mediated K⁺ influx, the MOM ruptures with loss of cytochrome *c* [65].

Uptake of K⁺ salts and osmotically obligated water leads to increased matrix volume (“ΔV” in Fig. 4), which is the basis of the light scattering (LS) assay for mitoK_{ATP} activity [65]. LS is the only practical method to study this process in isolated mitochondria, because mitoK_{ATP}-dependent K⁺ flux is rapid ($t_{1/2} \sim 30$ s) and small in magnitude. This technique has been successfully employed by several laboratories to measure K⁺ flux in mitochondria [76–80].

MitoK_{ATP}-dependent matrix alkalinization plays an essential role in intramitochondrial signaling. It causes Complex I to produce increased amounts of superoxide and its products, H₂O₂ and hydroxyl anion radical [66]. As seen below, the ROS produced by this mechanism play two important roles in cardioprotection, through their ability to activate PKCε.

We note that each of the consequences of mitoK_{ATP} opening are due specifically to the increased K⁺ influx. Thus, valinomycin (approximately 1 pmol/mg mitochondria) duplicates the effects of KCO on K⁺ uptake, respiration, matrix alkalinization, volume increase, and ROS production [65,66].

4.3 Step three - activation of PKCε by endogenous ROS

4.3.1 ROS activation of PKCε2 and inhibition of MPT—The increased ROS activates a second mitochondrial PKCε, “PKCε2” in Fig. 4, which inhibits the mitochondrial permeability transition (“MPT”) in a phosphorylation-dependent reaction [12]. H₂O₂ and NO, but not superoxide, also activate PKCε2 and inhibit MPT [12,32]. The dichotomy between protective and damaging ROS was strikingly demonstrated in an experiment in which 100 μM H₂O₂ plus 2 μM free Ca²⁺ were used to induce MPT opening in heart mitochondria. This ROS-induced MPT opening was inhibited when the mitochondria were first conditioned with 2 μM H₂O₂ [12]. Thus, cardioprotective mitoK_{ATP} opening leads to inhibition of MPT, and, therefore, to reduction of cell death after ischemia-reperfusion injury [5,6,11].

The evidence for two distinct mitochondrial PKCε is that the specific agonist ΨεRACK can activate PKCε1 and open mitoK_{ATP}, but it cannot activate the PKCε that regulates MPT [12]. This establishes a clear difference between the two PKCεs. Our tentative explanation for the observation is that PKCε2 faces the matrix side of the inner membrane. ΨεRACK is an anionic peptide that cannot enter the matrix, whereas εV₁₋₂, which inhibits both PKCε1 and PKCε2, can readily enter the matrix.

4.3.2 ROS activation of PKCε1 and feedback mitoK_{ATP} opening—The mitoK_{ATP}-dependent increase in ROS plays an additional role in cardioprotection. Note in Fig. 4 that PKCε1 is bypassed when KCOs are administered to the heart; however, we have found that PKCε1 is soon activated by mitoK_{ATP}-dependent ROS, leading to a persistent phosphorylation-dependent open state of mitoK_{ATP} [32]. These data define a new, positive feedback loop for mitoK_{ATP} opening, whose existence, which has been suggested by a number of authors [81–83], means that mitoK_{ATP} may be either upstream or downstream of PKCε, depending on the triggering stimulus. We suggest that feedback phosphorylation of mitoK_{ATP} is the mechanism of memory, which is seen with all PC triggers [84,85]. Thus, cardioprotective stimuli can be washed away from the system and the perfused heart remains protected from a major ischemic assault, thanks to phosphorylation of mitoK_{ATP}. We infer, but have not demonstrated, that mitoK_{ATP} opening is eventually reversed by an endogenous phosphatase (“PP2A” in Fig. 4) within the intermembrane space. For example, PP2A has been found in mitochondria where it is activated by proapoptotic factors [86].

4.4 Intramitochondrial signaling and the literature

The model in Fig. 4 helps to support and extend results of previous studies. Jiang *et al* [87] observed PKC and 5-HD regulation of the human cardiac mitoK_{ATP} in lipid bilayers. Garg and Hu [88] showed that PKC ϵ modulates mitoK_{ATP} activity in cardiomyocytes and COS-7 cells. Penna *et al* [89] demonstrated that protection by postconditioning protection involves a redox mechanism and persistent activation of mitoK_{ATP} and PKC. Facundo *et al.* [80] showed that H₂O₂ induces mitoK_{ATP} activity in isolated mitochondria, but did not identify participation of PKC ϵ . Zhang *et al.* [90] found that superoxide anion activated mitoK_{ATP} in planar bilayers, and we showed that this effect is mediated, not by superoxide, but by H₂O₂ acting indirectly via PKC ϵ 1 [32]. Sasaki, et al. [91] suggested that NO may open mitoK_{ATP} directly; however mitoK_{ATP} opening by NO is blocked by ϵ V₁₋₂ [32], showing that NO opens mitoK_{ATP} indirectly through PKC ϵ 1. Several authors have shown that exogenous and endogenous NO are cardioprotective and have attributed this effect to MPT inhibition [92–95]. Brookes, et al. [92] showed that NO inhibited MPT and cytochrome *c* release in isolated liver mitochondria. We showed that this effect occurs via activation of PKC ϵ 2 [32]. Korge, et al. [96] found that diazoxide prevented MPT opening and cytochrome *c* loss, and that both effects were mimicked by the PKC activator PMA and blocked by 5-HD. Kim, et al. [97] found that a cytosolic extract, together with cGMP and ATP, blocked MPT in isolated mitochondria, an effect that was blocked by PKG inhibition. Forbes, et al [98] and Pain, et al [85] found that N-acetylcysteine or MPG reversed the protective effect of diazoxide in perfused hearts. Our data suggests that blockade of protection occurred because mitoK_{ATP}-dependent ROS was scavenged and unavailable to activate PKC ϵ 2 and inhibit MPT. Lebuffe, et al [81] found that PMA-induced protection was blocked by 5-HD and that this block was reversed by coadministration of H₂O₂ and NO. This is also consistent with the model of Fig. 4 in that H₂O₂ and NO can bypass the blocked mitoK_{ATP} and act directly on PKC ϵ 2, thereby inhibiting MPT and protecting the heart.

5. Other mitochondrial mechanisms of cardioprotection

5.1 K_{ATP} channel openers (KCO)

KCOs have been shown to be cardioprotective in all species examined [99,100]. The ability of KCOs to open mitoK_{ATP} in their therapeutic dose range was described in 1996 [101]. Diazoxide was 1000 times more potent in opening mitoK_{ATP} than in opening sarcK_{ATP}, making diazoxide a valuable tool to determine whether cardioprotection was mediated by the sarcolemmal or the mitochondrial K_{ATP} channel. It was found that diazoxide was as effective as cromakalim in protecting the heart. Moreover, diazoxide protection, unlike that mediated by cromakalim, was not accompanied by APD shortening, thus demonstrating that cardioprotection was not due to sarcK_{ATP} opening. These findings led to the hypothesis that mitoK_{ATP} is the receptor that mediates the cardioprotective effects of KCOs [101,102]. KCOs act on the regulatory sulfonyleurea receptors (SUR) of K_{ATP} channels. Pinacidil, cromakalim, and nicorandil are effective openers of cardiac K_{ATP} through their action on SUR2A, but ineffective on pancreatic beta cell K_{ATP}, which uses SUR1. Conversely, diazoxide is an effective opener of beta cell K_{ATP}, but ineffective on the cardiac channel [101,103]. All KCOs we have examined open mitoK_{ATP} and protect the heart [65,101,102,104–108].

5.2 glycogen synthase kinase -3 β (GSK-3 β)

The GSK-3 β inhibitors lithium and SB 216763 are cardioprotective. IPC and diazoxide cause phosphorylation and inactivation of GSK-3 β [83,109], suggesting that GSK-3 β may be downstream of mitoK_{ATP}. Inhibition of GSK-3 β has no effect on MPT opening in isolated mitochondria [32], suggesting that the GSK isoform that interferes with cardioprotection resides outside of mitochondria. Importantly, cardioprotection by GSK-3 β inhibition is blocked

by 5-HD [110], indicating that the ultimate deleterious effect of GSK-3 β activity may be to cause mitoK_{ATP} inhibition.

5.3 Amobarbital

Amobarbital, administered 1 min before 25 min global ischemia, is cardioprotective in rat, causing marked improvement of contractile function and reduction of infarct size [111]. Amobarbital is a short-acting barbiturate that is a classic, reversible inhibitor of Complex I at the rotenone site. Amobarbital treatment was associated with preservation of cytochrome *c* [111], which is otherwise released after ischemia-reperfusion, due in part to oxidative degradation of cardiolipin [112]. Cardioprotection by amobarbital is consistent with the authors' overall hypothesis that ROS arising from Complex III during ischemia causes mitochondrial damage that contributes to myocardial injury during reperfusion [113].

5.4 Bromoenol lactone (BEL)

BEL, administered before global ischemia, is cardioprotective in rat [114] and rabbit [115], causing marked reduction of infarct size. BEL is a specific inhibitor of calcium-independent phospholipase A(2) (iPLA2), which is the major phospholipase A(2) in myocardium and is present in heart mitochondria [115]. Ischemia causes fatty acid accumulation in the heart, caused by phospholipases-mediated degradation of membrane phospholipids [112,116,117]. Protection by BEL was reversed, in both rat and rabbit hearts, by the simultaneous perfusion of 5-HD, implying participation of mitoK_{ATP}.

5.5 Hydrogen sulfide

H₂S, administered before global ischemia, is cardioprotective in rat [118–120]. H₂S is synthesized in the heart and other tissues by cystathionine λ -lyase. Cytoplasmic [H₂S] is determined by the balance between its constitutive production and its oxidation by mitochondria. When tissue oxygen levels fall, H₂S oxidation decreases, and [H₂S] increases, and Olson, et al. [121] consider H₂S to be the oxygen sensor of cells. Protection by H₂S was abolished by chelerythrine, implicating participation of PKC [119]. Infarct size reduction by H₂S was also abolished by glibenclamide and 5-HD, implicating participation of mitoK_{ATP} in H₂S protection [120]. H₂S increased the open probability of sarcolemmal K_{ATP} in cardiomyocytes [122] and may have a similar effect on mitoK_{ATP}.

5.6 Mitochondrial aldehyde dehydrogenase (ALDH2)

An activator of ALDH2, administered before global ischemia, is cardioprotective in rat, causing marked reduction of infarct size [123]. This recent discovery was the result of a directed proteomic search. The authors speculate that protection by ALDH2 activation is due to its metabolism of cytotoxic aldehydes, such as 4-hydroxynonenol.

5.7 Ca²⁺-activated mitochondrial K⁺ channel (mitoK_{Ca})

NS1619, an activator of the large conductance mitoK_{Ca} is cardioprotective in guinea pig, and protection is blocked by the inhibitor paxilline [124–126]. Sato, et al [127] found that there was no cross-talk between mitoK_{ATP} and mitoK_{Ca} — that is, paxilline blocked effects of NS1619 but not diazoxide, and 5-HD blocked effects of diazoxide but not NS1619. Cao et al. [125] observed similar absence of cross-talk in cardioprotection experiments. The latter findings suggest distinct channels with distinct pharmacology and suggest that these two channels constitute alternative mechanisms for raising matrix K⁺ and generating ROS.

6. Summary

Recent years have brought robust advances in our understanding of cardiac signal transduction during cardioprotection against ischemia-reperfusion and the pivotal role of mitochondria in these processes. This review exposes our current understanding of the mechanistic link between plasma membrane receptors and MPT, the ultimate mitochondrial target of cardioprotection. We suggest that interaction of the cardioprotective ligand with its receptor induces the formation of a signaling platform that is scaffolded by caveolins, that contains the activated enzymes of the pathway, and that is delivered to mitochondria as a signalosome. We believe that the signalosome mechanism [39] provides a means to resolve the mystery of receptor-specificity described by Downey, et al. [14]: “*It is still a mystery how identical Gi proteins, when activated by binding of the different agonists to their individual receptors, can initiate such distinct signaling pathways.*”

This review also points to several areas that require further investigation as to how signalosomes are directed to mitochondria, how cytoskeleton is involved, and what receptors are involved at the mitochondrial level. Even in light of these questions, the elucidation of the interactions among signaling components and mitochondria is a valuable tool for understanding the molecular controls in the decision between cell survival and cell death.

References

- Jennings RB, Ganote CE. Mitochondrial structure and function in acute myocardial ischemic injury. *Circ Res* 1976;38:180–191. [PubMed: 1269093]
- Droge W. Free radicals in the physiological control of cell function. *Physiol Rev* 2002;82:47–95. [PubMed: 11773609]
- Turrens JF. Mitochondrial formation of reactive oxygen species. *J Physiol* 2003;552:335–344. [PubMed: 14561818]
- Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. *Circ Res* 2003;93:292–301. [PubMed: 12933700]
- Crompton M. The mitochondrial permeability transition pore and its role in cell death. *Biochem J* 1999;341:233–249. [PubMed: 10393078]
- Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD⁺ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. *J Biol Chem* 2001;276:2571–2575. [PubMed: 11073947]
- Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? *Cardiovasc Res* 2002;55:534–543. [PubMed: 12160950]
- Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. *Cardiovasc Res* 2006;70:191–199. [PubMed: 16497286]Epub 2006 Feb 23
- Argaud L, Loufouat J, Gateau-Roesch O, Gomez L, Robert D, Ovize M. Persistent Inhibition of Mitochondrial Permeability Transition by Preconditioning During the First Hours of Reperfusion. *Shock* 2008;28:28.
- Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. *Cardiovasc Res* 2006;70:264–273. [PubMed: 16581044]
- Argaud L, Gateau-Roesch O, Raisy O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. *Circulation* 2005;111:194–197. [PubMed: 15642769]Epub 2005 Jan 10.
- Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The mechanism by which mitoK_{ATP} opening and H₂O₂ inhibit the mitochondrial permeability transition. *J Biol Chem* 2006;281:20801–20808. [PubMed: 16720572]

13. Budas GR, Mochly-Rosen D. Mitochondrial protein kinase Cepsilon (PKCepsilon): emerging role in cardiac protection from ischaemic damage. *Biochem Soc Trans* 2007;35:1052–1054. [PubMed: 17956277]
14. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. *Heart Fail Rev* 2007;12:181–188. [PubMed: 17516169]
15. Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. *Annu Rev Physiol* 2007;69:51–67. [PubMed: 17007587]
16. Gross ER, Gross GJ. Ligand triggers of classical preconditioning and postconditioning. *Cardiovasc Res* 2006;70:212–221. [PubMed: 16448635]
17. Liem DA, Honda HM, Zhang J, Woo D, Ping P. Past and present course of cardioprotection against ischemia-reperfusion injury. *J Appl Physiol* 2007;103:2129–2136. [PubMed: 17673563] Epub 2007 Aug 2.
18. Di Lisa F, Canton M, Menabo R, Kaludercic N, Bernardi P. Mitochondria and cardioprotection. *Heart Fail Rev* 2007;12:249–260. [PubMed: 17516167]
19. Cohen MV, Downey JM. Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. *Annual Review Of Medicine* 1996;47:21–29.
20. Banerjee A, Locke-Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, Bensard DD, Harken AH. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. *Circulation Research* 1993;73:656–670. [PubMed: 8396503]
21. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. *J Mol Cell Cardiol* 1995;27:883–892. [PubMed: 7602606]
22. Wang P, Gallagher KP, Downey JM, Cohen MV. Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. *J Mol Cell Cardiol* 1996;28:579–588. [PubMed: 9011641]
23. Krieg T, Cui L, Qin Q, Cohen MV, Downey JM. Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF. *J Mol Cell Cardiol* 2004;36:435–443. [PubMed: 15010282]
24. Krieg T, Qin Q, McIntosh EC, Cohen MV, Downey JM. ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. *Am J Physiol* 2002;283:H2322–H2330.
25. Cohen MV, Yang XM, Liu GS, Heusch G, Downey JM. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K_{ATP} channels. *Circ Res* 2001;89:273–278. [PubMed: 11485978]
26. Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the K_{ATP} channel. *Am J Physiol* 1994;266:H829–H839. [PubMed: 8141383]
27. Sato T, Sasaki N, O'Rourke B, Marban E. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: A key step in ischemic preconditioning? *Circulation* 2000;102:800–805. [PubMed: 10942750]
28. Reshef A, Sperling O, Zoref-Shani E. Opening of K_{ATP} channels is mandatory for acquisition of ischemic tolerance by adenosine. *Neuroreport* 2000;11:463–465. [PubMed: 10718295]
29. Headrick JP, Gauthier NS, Morrison R, Matherne GP. Cardioprotection by K_{ATP} channels in wild-type hearts and hearts overexpressing A(1)-adenosine receptors. *Am J Physiol* 2000;279:H1690–H1697.
30. Costa AD, Pierre SV, Cohen MV, Downey JM, Garlid KD. cGMP Signaling in Pre- and Postconditioning: The Role of Mitochondria. *Cardiovasc Res* 2008;77:344–352. [PubMed: 18006449]
31. Pierre SV, Yang C, Yuan Z, Seminerio J, Mouas C, Garlid KD, Dos Santos P, Xie Z. Ouabain triggers preconditioning through activation of the Na,K-ATPase signaling cascade in rat hearts. *Cardiovasc Res* 2007;73:488–496. [PubMed: 17157283]
32. Costa ADT, Garlid KD. Intramitochondrial signaling: interactions among $mitoK_{ATP}$, PKC ϵ , ROS, and MPT. *Am J Physiol* 2008;295:H874–H882.

33. Xie Z, Cai T. Na⁺-K⁺--ATPase-mediated signal transduction: from protein interaction to cellular function. *Mol Interv* 2003;3:157–168. [PubMed: 14993422]
34. Pierre SV, Xie Z. The Na,K-ATPase Receptor Complex: Its Organization and Membership. *Cell Biochem Biophys* 2006;46:303–316. [PubMed: 17272855]
35. Tian J, Liu J, Garlid KD, Shapiro JI, Xie Z. Involvement of Mitogen-activated Protein Kinases and Reactive Oxygen Species in the Inotropic Action of Ouabain on Cardiac Myocytes. A Potential Role for Mitochondrial K_{ATP} Channels. *Mol Cell Biochem* 2003;242:181–187. [PubMed: 12619881]
36. Pasdois PP, Quinlan CL, Rissa A, Tariosse L, Vinassa B, Pierre SV, Dos Santos P, Garlid KD. Ouabain protects rat hearts against ischemia-reperfusion injury via a pathway involving src kinase, mitoK_{ATP}, and ROS. *Am J Physiol* 2007;292:H1470–H1478.
37. D'Urso G, Frascarelli S, Zucchi R, Biver T, Montali U. Cardioprotection by Ouabain and Digoxin in Perfused Rat Hearts. *J Cardiovasc Pharmacol* 2008;10:10.
38. Garlid KD, Puddu PE, Pasdois P, ADT Costa, Beauvoit B, Criniti A, Tariosse L, Diolez P, Dos Santos P. Inhibition of cardiac contractility by 5-hydroxydecanoate and tetraphenylphosphonium ion: a possible role of mitoK_{ATP} in the response to inotropic stress. *Am J Physiol* 2006;291:H152–H160.
39. Quinlan CL, ADT Costa, Costa CL, Pierre SV, Dos Santos P, Garlid KD. Conditioning the Heart Induces Formation of Signalosomes that Interact with Mitochondria to Open MitoK_{ATP}. *Amer J Phys* 2008;295:H953–961.
40. Garlid KD. The state of water in biological systems. *Int Rev Cytol* 2000;192:281–302. [PubMed: 10553283]
41. Ping P, Zhang J, Pierce WM Jr, Bolli R. Functional proteomic analysis of protein kinase C epsilon signaling complexes in the normal heart and during cardioprotection. *Circ Res* 2001;88:59–62. [PubMed: 11139474]
42. Vondriska TM, Pass JM, Ping P. Scaffold proteins and assembly of multiprotein signaling complexes. *J Mol Cell Cardiol* 2004;37:391–397. [PubMed: 15276009]
43. Lisanti MP, Scherer PE, Tang Z, Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. *Trends Cell Biol* 1994;4:231–235. [PubMed: 14731661]
44. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. *J Biol Chem* 1997;272:6525–6533. [PubMed: 9045678]
45. Prabhakar P, Thatte HS, Goetz RM, Cho MR, Golan DE, Michel T. Receptor-regulated translocation of endothelial nitric-oxide synthase. *J Biol Chem* 1998;273:27383–27388. [PubMed: 9765266]
46. Escruche M, Burgueno J, Ciruela F, Canela EI, Mallol J, Enrich C, Lluís C, Franco R. Ligand-induced caveolae-mediated internalization of A1 adenosine receptors: morphological evidence of endosomal sorting and receptor recycling. *Exp Cell Res* 2003;285:72–90. [PubMed: 12681288]
47. Maniatis NA, Brovkovich V, Allen SE, John TA, Shajahan AN, Tiruppathi C, Vogel SM, Skidgel RA, Malik AB, Minshall RD. Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. *Circ Res* 2006;99:870–877. [PubMed: 16973909]
48. Patel HH, Head BP, Petersen HN, Niesman IR, Huang D, Gross GJ, Insel PA, Roth DM. Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and delta opioid receptors. *Am J Physiol* 2006;291:H344–H350.
49. Patel, HH.; Tsutsumi, YM.; Head, BP.; Niesman, IR.; Jennings, M.; Horikawa, Y.; Huang, D.; Moreno, AL.; Patel, PM.; Insel, PA.; Roth, DM. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. *Faseb J*. 2007. In press
50. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, Lisanti MP. Caveolins, liquid-ordered domains, and signal transduction. *Mol Cell Biol* 1999;19:7289–7304. [PubMed: 10523618]
51. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. *Pharmacol Rev* 2002;54:431–467. [PubMed: 12223531]
52. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. *J Biol Chem* 1995;270:15693–15701. [PubMed: 7797570]

53. Xie Z, Cai T. Na⁺-K⁺-ATPase-mediated signal transduction: from protein interaction to cellular function. *Mol Interv* 2003;3:157–168. [PubMed: 14993422]
54. Trincavelli ML, Tuscano D, Marroni M, Klotz KN, Lucacchini A, Martini C. Involvement of mitogen protein kinase cascade in agonist-mediated human A(3) adenosine receptor regulation. *Biochim Biophys Acta* 2002;1591:55–62. [PubMed: 12183055]
55. Franco R, Ciruela F, Casado V, Cortes A, Canela EI, Mallol J, Agnati LF, Ferre S, Fuxe K, Lluís C. Partners for adenosine A1 receptors. *J Mol Neurosci* 2005;26:221–232. [PubMed: 16012195]
56. Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E. G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. *Circ Res* 2004;94:1133–1141. [PubMed: 15031261]
57. Nichols B. Caveosomes and endocytosis of lipid rafts. *J Cell Sci* 2003;116:4707–4714. [PubMed: 14600257]
58. Haasemann M, Cartaud J, Muller-Esterl W, Dunia I. Agonist-induced redistribution of bradykinin B2 receptor in caveolae. *J Cell Sci* 1998;111:917–928. [PubMed: 9490636]
59. Pizarro A, Blaukat A, Muller-Esterl W, Alhenc-Gelas F, Rajerison RM. Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. *J Biol Chem* 1999;274:12738–12747. [PubMed: 10212257]
60. Trincavelli ML, Tuscano D, Cecchetti P, Falleni A, Benzi L, Klotz KN, Gremigni V, Cattabeni F, Lucacchini A, Martini C. Agonist-induced internalization and recycling of the human A(3) adenosine receptors: role in receptor desensitization and resensitization. *J Neurochem* 2000;75:1493–1501. [PubMed: 10987829]
61. Liu J, Kesiry R, Periyasamy SM, Malhotra D, Xie Z, Shapiro JJ. Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. *Kidney Int* 2004;66:227–241. [PubMed: 15200429]
62. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, Critz SD. Protein Kinase G Transmits the Cardioprotective Signal From Cytosol to Mitochondria. *Circ Res* 2005;97:329–336. [PubMed: 16037573]
63. Garlid KD. Cation transport in mitochondria--the potassium cycle. *Biochim Biophys Acta* 1996;1275:123–126. [PubMed: 8688444]
64. Jaburek M, ADT Costa, Burton JR, Costa CL, Garlid KD. Mitochondrial PKCepsilon and mitoK_{ATP} co-purify and co-reconstitute to form a functioning signaling module in proteoliposomes. *Circ Res* 2006;99:878–883. [PubMed: 16960097]
65. Costa ADT, Quinlan C, Andrukhiv A, West IC, Garlid KD. The direct physiological effects of mitoK_{ATP} opening on heart mitochondria. *Am J Physiol* 2006;290:H406–H415.
66. Andrukhiv A, Costa AD, West IC, Garlid KD. Opening mitoK_{ATP} increases superoxide generation from Complex I of the electron transport chain. *Am J Physiol* 2006;291:H2067–H2074.
67. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. *Biochem J* 2004;384:449–459. [PubMed: 15491280]
68. Kazanietz MG, Bustelo XR, Barbacid M, Kolch W, Mischak H, Wong G, Pettit GR, Bruns JD, Blumberg PM. Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. *J Biol Chem* 1994;269:11590–11594. [PubMed: 8157692]
69. Korichneva I, Hoyos B, Chua R, Levi E, Hammerling U. Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen. *J Biol Chem* 2002;277:44327–44331. [PubMed: 12213816]
70. Ron D, Mochly-Rosen D. An autoregulatory region in protein kinase C: the pseudoanchoring site. *Proc Natl Acad Sci U S A* 1995;92:492–496. [PubMed: 7831317]
71. Johnson JA, Gray MO, Chen CH, Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. *J Biol Chem* 1996;271:24962–24966. [PubMed: 8798776]
72. Souroujon MC, Mochly-Rosen D. Peptide modulators of protein-protein interactions in intracellular signaling. *Nat Biotechnol* 1998;16:919–924. [PubMed: 9788346]

73. Murriel CL, Mochly-Rosen D. Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. *Arch Biochem Biophys* 2003;420:246–254. [PubMed: 14654063]
74. Garlid KD, Paucek P. Mitochondrial potassium transport: the K⁺ cycle. *Biochim Biophys Acta* 2003;1606:23–41. [PubMed: 14507425]
75. Beavis AD, Garlid KD. Evidence for the allosteric regulation of the mitochondrial K⁺/H⁺ antiporter by matrix protons. *J Biol Chem* 1990;265:2538–2545. [PubMed: 2154450]
76. Pastore D, Stoppelli MC, Di Fonzo N, Passarella S. The existence of the K(+) channel in plant mitochondria. *J Biol Chem* 1999;274:26683–26690. [PubMed: 10480870]
77. Rousou AJ, Ericsson M, Federman M, Levitsky S, McCully JD. Opening of mitochondrial KATP channels enhances cardioprotection through the modulation of mitochondrial matrix volume, calcium accumulation, and respiration. *Am J Physiol* 2004;287:H1967–H1976. Epub 2004 Jul 8.
78. Riess ML, Costa AD, Carlson R Jr, Garlid KD, Heinen A, Stowe DF. Differential increase of mitochondrial matrix volume by sevoflurane in isolated cardiac mitochondria. *Anesth Analg* 2008;106:1049–1055. [PubMed: 18349172]
79. Wojtovich, AP.; Brookes, PS. The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: Implications for ischemic preconditioning. *Biochim Biophys Acta*. 2008.
80. Facundo HT, de Paula JG, Kowaltowski AJ. Mitochondrial ATP-sensitive K(+) channels are redox-sensitive pathways that control reactive oxygen species production. *Free Radic Biol Med* 2007;42:1039–1048. [PubMed: 17349931] Epub 2007 Jan 8.
81. Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, Vanden Hoek TL. ROS and NO trigger early preconditioning: relationship to mitochondrial K_{ATP} channel. *Am J Physiol* 2003;284:H299–H308.
82. Kevin LG, Camara AKS, Riess ML, Novalija E, Stowe DF. Ischemic preconditioning alters real-time measure of O₂ radicals in intact hearts with ischemia and reperfusion. *Am J Physiol* 2003;284:H566–574.
83. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. *J Clin Invest* 2004;113:1535–1549. [PubMed: 15173880]
84. Downey JM, Cohen MV. Signal transduction in ischemic preconditioning. *Adv Exp Med Biol* 1997;430:39–55. [PubMed: 9330717]
85. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, Liu GS, Heusch G, MV Cohen, Downey JM. Opening of mitochondrial K_{ATP} channels triggers the preconditioned state by generating free radicals. *Circ Res* 2000;87:460–466. [PubMed: 10988237]
86. Klumpp S, Krieglstein J. Serine/threonine protein phosphatases in apoptosis. *Curr Opin Pharmacol* 2002;2:458–462. [PubMed: 12127881]
87. Jiang MT, Ljubkovic M, Nakae Y, Shi Y, Kwok WM, Stowe DF, Bosnjak ZJ. Characterization of human cardiac mitochondrial ATP-sensitive potassium channel and its regulation by phorbol ester in vitro. *Am J Physiol* 2006;290:H1770–H1776.
88. Garg V, Hu K. Protein kinase C isoform-dependent modulation of ATP-sensitive K⁺ channels in mitochondrial inner membrane. *Am J Physiol* 2007;293:H322–H332.
89. Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S, Gattullo D, Losano G, Pagliaro P. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K⁺ channel and protein kinase C activation. *Basic Res Cardiol* 2006;101:180–189. [PubMed: 16450075]
90. Zhang, DX.; Chen, YF.; Campbell, WB.; Zou, AP.; Gross, GJ.; Li, PL. Characteristics and superoxide-induced activation of reconstituted myocardial mitochondrial ATP-sensitive potassium channels. *Circ Res*. 2001. In press
91. Sasaki N, Sato T, Ohler A, O'Rourke B, Marban E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. *Circulation* 2000;101:439–445. [PubMed: 10653837]

92. Brookes PS, Salinas EP, Darley-USmar K, Eiserich JP, Freeman BA, Darley-USmar VM, Anderson PG. Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. *J Biol Chem* 2000;275:20474–20479. [PubMed: 10791954]
93. Kim JS, Ohshima S, Padiaditakis P, Lemasters JJ. Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition. *Hepatology* 2004;39:1533–1543. [PubMed: 15185294]
94. Wang G, Liem DA, Vondriska TM, Honda HM, Korge P, Pantaleon DM, Qiao X, Wang Y, Weiss JN, Ping P. Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. *Am J Physiol* 2005;288:H1290–H1295.
95. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. *J Mol Cell Cardiol* 2006;40:16–23. [PubMed: 16288777]
96. Korge P, Honda HM, Weiss JN. Protection of cardiac mitochondria by diazoxide and protein kinase C: implications for ischemic preconditioning. *Proc Natl Acad Sci U S A* 2002;99:3312–3317. [PubMed: 11867760]
97. Kim JS, Ohshima S, Padiaditakis P, Lemasters JJ. Nitric oxide: a signaling molecule against mitochondrial permeability transition- and pH-dependent cell death after reperfusion. *Free Radic Biol Med* 2004;37:1943–1950. [PubMed: 15544914]
98. Forbes RA, Steenbergen C, Murphy E. Diazoxide-Induced Cardioprotection Requires Signaling Through a Redox-Sensitive Mechanism. *Circ Res* 2001;88:802–809. [PubMed: 11325872]
99. Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. *J Pharmacol Exp Ther* 1989;251:98–104. [PubMed: 2507775]
100. Grover GJ, Garlid KD. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. *J Mol Cell Cardiol* 2000;32:677–695. [PubMed: 10756123]
101. Garlid KD, Paucek P, Yarov-Yarovoy V, Sun X, Schindler PA. The mitochondrial K_{ATP} channel as a receptor for potassium channel openers. *J Biol Chem* 1996;271:8796–8799. [PubMed: 8621517]
102. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K^+ channels. Possible mechanism of cardioprotection. *Circ Res* 1997;81:1072–1082. [PubMed: 9400389]
103. Moreau C, Jacquet H, Prost AL, D'Hahan N, Vivaudou M. The molecular basis of the specificity of action of K_{ATP} channel openers. *Embo J* 2000;19:6644–6651. [PubMed: 11118199]
104. Jaburek M, Yarov-Yarovoy V, Paucek P, Garlid KD. State-dependent inhibition of the mitochondrial K_{ATP} channel by glyburide and 5-hydroxydecanoate. *J Biol Chem* 1998;273:13578–13582. [PubMed: 9593694]
105. Puddu PE, Garlid KD, Monti F, Iwashiro K, Picard S, Dawodu AA, Criniti A, Ruvolo G, Campa PP. Bimakalim: A promising K_{ATP} channel activating agent. *Cardiovasc Drug Rev* 2000;18:25–46.
106. Kowaltowski AJ, Seetharaman S, Paucek P, Garlid KD. Bioenergetic consequences of opening the ATP-sensitive K^+ channel of heart mitochondria. *Am J Physiol* 2001;280:H649–H657.
107. Grover GJ, D'Alonzo AJ, Garlid KD, Bajjar R, Lodge NJ, Sleph PG, Darbenzio RB, Hess TA, Smith MA, Paucek P, Atwal KS. Pharmacologic characterization of BMS-191095, a mitochondrial K_{ATP} opener with no peripheral vasodilator or cardiac action potential shortening activity. *J Pharmacol Exp Ther* 2001;297:1184–1192. [PubMed: 11356945]
108. Oldenburg O, Yang XM, Krieg T, Garlid KD, Cohen MV, Grover GJ, Downey JM. P1075 opens mitochondrial K_{ATP} channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts. *J Mol Cell Cardiol* 2003;35:1035–1042. [PubMed: 12967626]
109. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase--dependent pathway is cardioprotective. *Circ Res* 2002;90:377–379. [PubMed: 11884365]
110. Gross ER, Hsu AK, Gross GJ. GSK3beta inhibition and $K(ATP)$ channel opening mediate acute opioid-induced cardioprotection at reperfusion. *Basic Res Cardiol* 2007;102:341–349. [PubMed: 17450314]Epub 2007 Apr 23

111. Chen Q, Moghaddas S, Hoppel CL, Lesnefsky EJ. Reversible blockade of electron transport during ischemia protects mitochondria and decreases myocardial injury following reperfusion. *J Pharmacol Exp Ther* 2006;319:1405–1412. [PubMed: 16990510]Epub 2006 Sep 21
112. Lesnefsky EJ, Slabe TJ, Stoll MS, Minkler PE, Hoppel CL. Myocardial ischemia selectively depletes cardiolipin in rabbit heart subsarcolemmal mitochondria. *Am J Physiol Heart Circ Physiol* 2001;280:H2770–H2778. [PubMed: 11356635]
113. Chen Q, Moghaddas S, Hoppel CL, Lesnefsky EJ. Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. *Am J Physiol Cell Physiol* 2008;294:C460–C466. [PubMed: 18077608]Epub 2007 Dec 12
114. Sargent CA, Wilde MW, Dzwonczyk S, Tuttle JG, Murray HN, Atwal K, Grover GJ. Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts. *Cardiovascular Research* 1996;31:270–277. [PubMed: 8730404]
115. Williams SD, Gottlieb RA. Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective. *Biochem J* 2002;362:23–32. [PubMed: 11829736]
116. Van der Vusse GJ, Roemen TH, Prinzen FW, Coumans WA, Reneman RS. Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. *Circ Res* 1982;50:538–546. [PubMed: 7067061]
117. Van der Vusse GJ, Reneman RS, van Bilsen M. Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences. *Prostaglandins Leukot Essent Fatty Acids* 1997;57:85–93. [PubMed: 9250613]
118. Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, Du J, Tang C. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem Biophys Res Commun* 2004;318:756–763. [PubMed: 15144903]
119. Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou S, Moore PK. Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. *J Pharmacol Exp Ther* 2006;316:670–678. [PubMed: 16204473]Epub 2005 Oct 4.
120. Johansen D, Ytrehus K, Baxter GF. Exogenous hydrogen sulfide (H₂S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K⁺ ATP channels. *Basic Res Cardiol* 2006;101:53–60. [PubMed: 16328106]Epub 2005 Nov 21
121. Olson KR, Dombkowski RA, Russell MJ, Doellman MM, Head SK, Whitfield NL, Madden JA. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol* 2006;209:4011–4023. [PubMed: 17023595]
122. Zhang Z, Huang H, Liu P, Tang C, Wang J. Hydrogen sulfide contributes to cardioprotection during ischemia-reperfusion injury by opening K⁺ ATP channels. *Can J Physiol Pharmacol* 2007;85:1248–1253. [PubMed: 18066126]
123. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. *Science* 2008;321:1493–1495. [PubMed: 18787169]
124. Xu W, Liu Y, Wang S, McDonald T, Van Eyk JE, Sidor A, O'Rourke B. Cytoprotective role of Ca²⁺-activated K⁺ channels in the cardiac inner mitochondrial membrane. *Science* 2002;298:1029–1033. [PubMed: 12411707]
125. Cao CM, Xia Q, Gao Q, Chen M, Wong TM. Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning. *J Pharmacol Exp Ther* 2005;312:644–650. [PubMed: 15345753]
126. Wang X, Yin C, Xi L, Kukreja RC. Opening of Ca²⁺-activated K⁺ channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. *Am J Physiol* 2004;287:H2070–H2077.
127. Sato T, Saito T, Saegusa N, Nakaya H. Mitochondrial Ca²⁺-activated K⁺ channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. *Circulation* 2005;111:198–203. [PubMed: 15623543]
128. Yang CM, Lin MI, Hsieh HL, Sun CC, Ma YH, Hsiao LD. Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells. *J Cell Physiol* 2005;203:538–546. [PubMed: 15573401]

129. Oldenburg O, Cohen MV, Downey JM. Mitochondrial K_{ATP} channels in preconditioning. *J Mol Cell Cardiol* 2003;35:569–575. [PubMed: 12788373]
130. Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, Cohen MV, Downey JM. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mito K_{ATP} channel opening and leads to cardioprotection. *Am J Physiol* 2004;286:H468–H476.
131. Oldenburg O, Critz SD, Cohen MV, Downey JM. Acetylcholine-induced production of reactive oxygen species in adult rabbit ventricular myocytes is dependent on phosphatidylinositol 3- and Src-kinase activation and mitochondrial K_{ATP} channel opening. *J Mol Cell Cardiol* 2003;35:653–660. [PubMed: 12788383]
132. Krieg T, Philipp S, Cui L, Dostmann WR, Downey JM, Cohen MV. Peptide blockers of PKG inhibit ROS generation by acetylcholine and bradykinin in cardiomyocytes but fail to block protection in the whole heart. *Am J Physiol Heart Circ Physiol* 2005;288:H1976–H1981. [PubMed: 15591097]




Figure 1. GPCR-mediated signaling to mitochondria

Occupation of the GPCR leads to activation of PI3-kinase, phosphorylation of phosphatidylinositol bisphosphate, and activation of the phosphatidylinositol-dependent kinases (PDKs) [128]. PDKs then phosphorylate Akt, which initiates the remainder of the cytosolic signaling pathway: endothelial nitric oxide synthase (eNOS) is phosphorylated, leading to production of NO. NO stimulates guanylyl cyclase, and the cGMP produced activates protein kinase G (PKG) [129], which causes mitoK_{ATP} opening [62,130–132].




Figure 2. Signal transmission by signalosome

It is proposed that interaction of bradykinin (and other GPCR agonists) or ouabain with their plasma membrane receptors induces formation of a vesicular caveolar signaling platform (signalosome) that phosphorylates receptor (R1 and R2) on the mitochondrial outer membrane (MOM). The terminal kinase of the bradykinin signalosome is PKG. The terminal kinases of the ouabain signalosome are PKCε and Src kinase. Following phosphorylation of the MOM receptor, the signal is transmitted across the intermembrane space to activate PKCε on the mitochondrial inner membrane. PKCε, in turn opens mitoK_{ATP} by a phosphorylation reaction [32].




Figure 3. Signalosomes from treated hearts induce mitoK_{ATP} opening in mitochondria from untreated hearts

Shown are changes in “MitoK_{ATP} activity (%)” when signalosome fractions from rat hearts treated with bradykinin, ouabain, ischemic preconditioning, or ischemic postconditioning were added to assay mitochondria from untreated rat hearts. Ischemic preconditioning consisted of two 5 min ischemia-reperfusion cycles, and ischemic postconditioning consisted of six 10 s cycles of ischemia-reperfusion. Also shown are the effects of PP2A (11 ng/mL) and KT5823 (“KT”, 0.5 μM) added to the assay. Note that PP2A cannot cross the MOM of intact mitochondria, so its effect is on the MOM. Data are averages ± SD of 3 to 4 independent experiments. The figure is from Quinlan, et al. [39].




Figure 4. The intramitochondrial signaling pathways

The pathways leading to mitoK_{ATP} opening, ROS production, and MPT inhibition are shown. Signals arising from G_i-coupled receptors are delivered to mitochondria via the terminal kinase PKG. Signals arising from ouabain action upon the Na-K ATPase are delivered to mitochondria via two terminal kinases, PKC ϵ and Src. The terminal kinases are localized in the signalosomes. PKG phosphorylates an unknown MOM receptor, “R1”, whereas PKC ϵ and Src act in conjunction to activate a distinct MOM receptor, “R2”. These MOM receptors transmit the signal by an unknown mechanism to PKC ϵ 1 located at the inner membrane. The activated PKC ϵ 1 phosphorylates and opens mitoK_{ATP}. PKC ϵ 1 activity is likely to be counteracted physiologically by Ser/Thr protein phosphatases (PPase) such as PP2A. MitoK_{ATP} opening via PKC ϵ 1 or by K_{ATP} channel openers such as diazoxide causes K⁺ uptake, increased matrix pH, and increased H₂O₂ production from Complex I. H₂O₂ produced by mitoK_{ATP} activity now diffuses and activates both PKC ϵ 1 and PKC ϵ 2. PKC ϵ 2 inhibits MPT, thus reducing cell necrosis and infarct size. The figure is from Costa and Garlid [32].




Figure 5. PKC ϵ -mediated mitoK_{ATP} opening

Changes in mitochondrial matrix volume (V) are plotted versus time. Rat heart mitochondria (0.1 mg/ml) were suspended in standard assay medium [32]. H₂O₂ (2 μ M) or $\Psi\epsilon$ RACK (0.5 μ M) were added to medium in the presence of ATP (0.2 mM) approximately one second after the mitochondria. Other additions to the assay medium were 5-HD (0.3 mM) and ϵV_{1-2} (0.5 μ M). Traces are representative of at least 5 independent experiments. The figure is from Costa and Garlid [32].